Next biotech runner...results imminenet

After BIT and MEM my next biotech target is Ftt
]

Number of reasons, firstly results readout is due anytime in the next few weeks.
If the results are good FTT will rip but the kicker here is the company has already gone down this path and had good results but the trial was deemed lacking. 20c should be on the cards here short term

Australian biomedical company Factor Therapeutics (ASX: FTT) is expecting “top line results” following the completion of a lengthy Phase 2 clinical trial of its VF001 drug for the treatment of venous leg ulcers.


At Factor’s annual meeting last month, management presented preliminary results based on 91 patients that had completed treatment.
By the end, 53 per cent were fully healed, with 50 per cent healing by week four and 70 per cent healing by week 12.

This compared with the standard of care UK trial, called Venus 3. In this 49-patient effort, 41 per cent were fully healed, with 50 per cent healing at week 10 and 55 per cent healing at week 12.


]In its Tissue days, Factor failed to win European approval for a VLU device despite a positive 53-patient trial. In 2011, Tissue Therapies said it expected European approval that year along with the start of a US trial and first sales in 2012.

In 2013, the company said that despite assurances from its European Medicines Agency (EMA) responsible entity the British Standards Institute that Vitrogro was a device and the EMA took a further two years to decide that the IGF-1 in the potion’s mixture was actually a drug, requiring a new trial.

Chief executive officer Dr Steven Mercer took the fall.
While the previous trial results were promising, the small size of the patient base raised issues which the current larger trial should obviate.

As above expecting 150% return short term